Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer (Q44775139)

6 December 2017

title

Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer (English)

1 reference

6 December 2017

1 reference

1 reference

Joshua B Greene

2

0 references

author name string

Joseph I Clark

1

1 reference

6 December 2017

Ann Lau Clark

3

1 reference

6 December 2017

Jay S Dalal

4

1 reference

6 December 2017

Craig C Hofmeister

5

1 reference

6 December 2017

publication date

25 December 2012

1 reference

6 December 2017

1 reference

6 December 2017

volume

30

1 reference

6 December 2017

issue

1

1 reference

6 December 2017

page(s)

358

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-012-0358-x

6 December 2017

exact match

0 references

cites work

Treatment of head and neck cancer: the role of chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0358-X

Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.

21 January 2018

1 reference

12 December 2020

Head and neck cancer: chemotherapy concepts.

1 reference

12 December 2020

Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.

1 reference

12 December 2020

Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts

1 reference

12 December 2020

The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells.

1 reference

12 December 2020

Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

12 December 2020

Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors

1 reference

12 December 2020

Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model

1 reference

12 December 2020

Pharmacokinetics and safety profile of oxaliplatin

1 reference

12 December 2020

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

1 reference

12 December 2020

IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab

1 reference

12 December 2020

10.1007/S12032-012-0358-X

Identifiers

DOI

1 reference

6 December 2017

1 reference